Shavit Capital

MeMed Diagnostics Ltd. is a personalized diagnostics company established in 2009 and based in Tirat Carmel, Israel. The firm specializes in developing diagnostic solutions that focus on distinguishing between bacterial and viral infections to enhance patient care and reduce healthcare costs. Its flagship product, MeMed BV, is a test that analyzes patients' immune responses to differentiate between infection types. Additionally, the ImmunoDx platform combines proprietary biomarkers and algorithms to provide rapid and actionable insights for healthcare professionals, thereby addressing the challenge of antibiotic misuse, which is prevalent in healthcare systems worldwide. By accurately identifying the source of infection, MeMed's diagnostics aim to prevent inappropriate antibiotic prescriptions, mitigate the emergence of resistant bacterial strains, and ultimately improve treatment outcomes for infectious diseases.

Lightricks Ltd. is a company based in Jerusalem, Israel, specializing in the development of mobile image processing applications. Founded in 2013 by a team of entrepreneurs with extensive experience in computer graphics, image processing, machine learning, and artificial intelligence, Lightricks aims to bridge the gap between advanced algorithms and accessible mobile editing tools. Its product lineup includes popular applications such as Facetune, a portrait and selfie editor; Enlight, a comprehensive photo-editing tool; and Beatleap, which facilitates audio-driven video editing. The company employs proprietary algorithms and augmented reality features to enhance user experience by enabling easy customization and editing of images. Lightricks serves a global audience, providing innovative solutions that combine advanced technology with user-friendly design.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Veev Inc., established in 2017 and based in Minneapolis, Minnesota, is a hybrid real estate solutions company that focuses on transforming the construction and experience of homes. The company offers an innovative home operating system that integrates room-specific lighting, shade, and climate control, while also safeguarding against security threats and cybercrime. Veev employs a panelized building system that utilizes light gauge steel for framing and high-performance acrylic for surfaces, complemented by radiant climate control systems and a digital home ecosystem. Currently, Veev is concentrating on high-performance multifamily units and accessory dwelling units (ADUs), with a development pipeline exceeding 230 units and 620,000 gross building square feet. Their comprehensive approach includes asset management, architectural design, permitting, modular construction, installation, and a digital infrastructure that enhances safety, maintenance, and overall comfort for homeowners.

Alpha Tau Medical LTD. researches, develops, and commercializes conformal treatment of solid tumors. It offers Alpha DaRT, a diffusing alpha-emitters radiation therapy for treating cancer in multiple animal studies. The company’s technology enables treatment of solid tumors with interstitial radioactive seeds. It also provides clinical trial services. Alpha Tau Medical LTD. was founded in 2016 and is headquartered in Tel Aviv, Israel.

Syqe Medical Ltd. transforms cannabis and other psychoactive botanicals into mainstream medical drugs and inhalers. It provides Syqe Inhaler Exo, a hospital version metered-dose cannabis inhaler for professional healthcare use, including pain clinics, cancer centers, intensive care units, and other medical institutions. The company was founded in 2011 and is based in Tel Aviv, Israel.

Alpha Tau Medical LTD. researches, develops, and commercializes conformal treatment of solid tumors. It offers Alpha DaRT, a diffusing alpha-emitters radiation therapy for treating cancer in multiple animal studies. The company’s technology enables treatment of solid tumors with interstitial radioactive seeds. It also provides clinical trial services. Alpha Tau Medical LTD. was founded in 2016 and is headquartered in Tel Aviv, Israel.

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.

PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID–500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

Mapi Pharma is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relationships in all of the countries in which it operates. Mapi is dedicated to providing generic and innovative intermediates and APIs, as well as developing finished dosage forms – either for Mapi’s internal API program, as a vertically integrated company, or as generics of leading brands. Mapi is headquartered in Israel. It has R&D facilities in Israel, China and Germany and is currently building an API manufacturing site in Neot Hovav, Israel’s designated chemical park. Mapi has a strong IP position, filing numerous patent applications for APIs and formulations.